Zai Lab application for omadacycline accepted in China

The China National Medical Products Administration has accepted for review Zai Lab’s (ZLAB +1%) marketing application seeking approval to use omadacycline to treat community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

The tetracycline antibiotic is sold in the U.S. under the brand name Nuzyra by licensor Paratek Pharmaceuticals (PRTK).

https://seekingalpha.com/news/3540042-zai-lab-application-for-omadacycline-accepted-in-china